Enhanced Solubility and Bioavailability of Naringenin via Liposomal Nanoformulation: Preparation and In Vitro and In Vivo Evaluations

被引:0
作者
Yuanwen Wang
Shicheng Wang
Caleb Kesse Firempong
Huiyun Zhang
Miaomiao Wang
Ya Zhang
Yuan Zhu
Jiangnan Yu
Ximing Xu
机构
[1] Jiangsu University,Department of Pharmaceutics, School of Pharmacy, Center for Nano Drug/Gene Delivery and Tissue Engineering
来源
AAPS PharmSciTech | 2017年 / 18卷
关键词
bioavailability; release; liposome; naringenin; tissue distribution;
D O I
暂无
中图分类号
学科分类号
摘要
This study was aimed at preparing orally administered naringenin-loaded liposome for pharmacokinetic and tissue distribution studies in animal models. The liposomal system, consisting of phospholipid, cholesterol, sodium cholate, and isopropyl myristate, was prepared using the thin-film hydration method. Physicochemical characterization of naringenin-loaded liposome such as particle size, zeta potential, and encapsulation efficiency produced 70.53 ± 1.71 nm, −37.4 ± 7.3 mV, and 72.2 ± 0.8%, respectively. The in vitro release profile of naringenin from the formulation in three different media (HCl solution, pH 1.2; acetate buffer solution, pH 4.5; phosphate buffer solution, pH 6.8) was significantly higher than the free drug. The in vivo studies also revealed an increase in AUC of the naringenin-loaded liposome from 16648.48 to 223754.0 ng·mL−1 h as compared with the free naringenin. Thus, approximately 13.44-fold increase in relative bioavailability was observed in mice after oral administration. The tissue distribution further showed that the formulation was very predominant in the liver. These findings therefore indicated that the liposomal formulation significantly improved the solubility and oral bioavailability of naringenin, thus leading to wider clinical applications.
引用
收藏
页码:586 / 594
页数:8
相关论文
共 173 条
[1]  
Shulman M(2011)Enhancement of naringenin bioavailability by complexation with hydroxypropoyl-β-cyclodextrin Plos ONE 6 160-78
[2]  
Cohen M(1999)Antiatherogenic properties of naringenin, a citrus flavonoid Cardiovasc Drug Rev 17 314-7
[3]  
Soto-Gutierrez A(1998)A method for measuring naringenin in biological fluids and its disposition from grapefruit juice by man Pharmacology 56 105-13
[4]  
Yagi H(2010)Naringenin inhibits neointimal hyperplasia following arterial reconstruction with interpositional vein graft Ann Plast Surg 64 475-107
[5]  
Wang H(1988)Action of S 5682 on the complement system. In vitro and in vivo study Int Angiol J Int Union Angiol 7 99-8(8)
[6]  
Goldwasser J(2011)Recent advances in understanding the antibacterial properties of flavonoids Int J Antimicrob Agents 38 681-6
[7]  
Wilcox LJ(2001)Anti-atherogenic effect of citrus flavonoids, naringin and naringenin, associated with hepatic ACAT and aortic VCAM-1 and MCP-1 in high cholesterol-fed rabbits Biochem Biophys Res Commun 284 72-90
[8]  
Borradaile NM(2004)The flavonoid naringenin inhibits dimethylnitrosamine-induced liver damage in rats Biol Pharm Bull 27 3684-9
[9]  
Huff MW(2008)Naringenin induces apoptosis through downregulation of Akt and caspase-3 activation in human leukemia THP-1 cells Food Chem Toxicol Int J Publ Br Ind Biol Res Assoc 46 2275-477
[10]  
Lee YS(1990)In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids Carcinogenesis 11 472-8